Mutations in XPR1 cause primary familial brain calcification associated with altered phosphate export.

Andrea Legati, Donatella Giovannini, Gaël Nicolas, Uriel López-Sánchez, Beatriz Quintáns, João R M Oliveira, Renee L Sears, Eliana Marisa Ramos, Elizabeth Spiteri, María-Jesús Sobrido, Ángel Carracedo, Cristina Castro-Fernández, Stéphanie Cubizolle, Brent L Fogel, Cyril Goizet, Joanna C Jen, Suppachok Kirdlarp, Anthony E Lang, Zosia Miedzybrodzka, Witoon Mitarnun, Martin Paucar, Henry Paulson, Jérémie Pariente, Anne-Claire Richard, Naomi S Salins, Sheila A Simpson, Pasquale Striano, Per Svenningsson, François Tison, Vivek K Unni, Olivier Vanakker, Marja W Wessels, Suppachok Wetchaphanphesat, Michele Yang, Francois Boller, Dominique Campion, Didier Hannequin, Marc Sitbon, Daniel H Geschwind, Jean-Luc Battini, Giovanni Coppola
Nat Genet. 2015-05-04; 47(6): 579-581
DOI: 10.1038/ng.3289

PubMed
Read on PubMed



1. Nat Genet. 2015 Jun;47(6):579-81. doi: 10.1038/ng.3289. Epub 2015 May 4.

Mutations in XPR1 cause primary familial brain calcification associated with
altered phosphate export.

Legati A(1), Giovannini D(2), Nicolas G(3), López-Sánchez U(2), Quintáns B(4),
Oliveira JR(5), Sears RL(1), Ramos EM(1), Spiteri E(6), Sobrido MJ(4), Carracedo
Á(4), Castro-Fernández C(4), Cubizolle S(7), Fogel BL(6), Goizet C(8), Jen JC(6),
Kirdlarp S(9), Lang AE(10), Miedzybrodzka Z(11), Mitarnun W(9), Paucar M(12),
Paulson H(13), Pariente J(14), Richard AC(15), Salins NS(16), Simpson SA(11),
Striano P(17), Svenningsson P(12), Tison F(7), Unni VK(18), Vanakker O(19),
Wessels MW(20), Wetchaphanphesat S(9), Yang M(21), Boller F(22), Campion D(23),
Hannequin D(24), Sitbon M(2), Geschwind DH(25), Battini JL(2), Coppola G(25).

Author information:
(1)Department of Psychiatry, David Geffen School of Medicine, University of
California, Los Angeles, Los Angeles, California, USA.
(2)1] Institut de Génétique Moléculaire de Montpellier, CNRS UMR 5535,
Montpellier, France. [2] Université de Montpellier, Montpellier, France. [3]
Laboratory of Excellence GR-Ex, Paris, France. [4] Laboratory of Excellence
EpiGenMed, Montpellier, France.
(3)1] INSERM U1079, Institute for Research and Innovation in Biomedicine (IRIB),
University of Rouen, Rouen, France. [2] Centre National de Référence pour les
Malades Alzheimer Jeunes (CNR-MAJ), Rouen University Hospital, Rouen, France. [3]
Department of Genetics, Rouen University Hospital, Rouen, France.
(4)1] Fundación Pública Galega de Medicina Xenómica, Servizo Galego de Saúde
(SERGAS), Instituto de Investigación Sanitaria (IDIS, Hospital Clínico
Universitario), Santiago de Compostela, Spain. [2] Grupo de Medicina Xenómica,
Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER,
Universidad de Santiago de Compostela), Santiago de Compostela, Spain.
(5)Keizo Asami Laboratory, Federal University of Pernambuco, Recife, Brazil.
(6)Department of Neurology, David Geffen School of Medicine, University of
California, Los Angeles, Los Angeles, California, USA.
(7)Neurology and Institute for Neurodegenerative Diseases, Bordeaux University
Hospital and Bordeaux University, Bordeaux, France.
(8)Service de Génétique Médicale, Bordeaux Hospital University Center, Bordeaux,
France.
(9)Division of Medicine, Buriram Hospital, Buriram, Thailand.
(10)1] Morton and Gloria Movement Disorders Clinic, Toronto Western Hospital,
Toronto, Ontario, Canada. [2] Edmond J. Safra Program in Parkinson’s Disease,
Toronto Western Hospital, Toronto, Ontario, Canada.
(11)Medical Genetics Group, School of Medicine and Dentistry, University of
Aberdeen, Aberdeen, UK.
(12)1] Translational Neuropharmacology, Clinical Neuroscience, Center for
Molecular Medicine, Karolinska Institute, Stockholm, Sweden. [2] Department of
Neurology, Karolinska University Hospital Huddinge, Stockholm, Sweden.
(13)Department of Neurology, University of Michigan, Ann Arbor, Michigan, USA.
(14)1] INSERM, Imagerie Cérébrale et Handicaps Neurologiques, UMR 825, Pole
Neurosciences, Centre Hospitalier Universitaire (CHU) Purpan, Toulouse, France.
[2] CHU de Toulouse, Université de Toulouse, Toulouse, France.
(15)1] INSERM U1079, Institute for Research and Innovation in Biomedicine (IRIB),
University of Rouen, Rouen, France. [2] Centre National de Référence pour les
Malades Alzheimer Jeunes (CNR-MAJ), Rouen University Hospital, Rouen, France.
(16)Barrow Neurological Institute, Phoenix, Arizona, USA.
(17)Pediatric Neurology and Muscular Diseases Unit, Department of Neurosciences,
Rehabilitation, Ophthalmology, Genetics, and Maternal and Child Health,
University of Genoa ‘G. Gaslini’ Institute, Genoa, Italy.
(18)Department of Neurology, Oregon Health and Science University, Portland,
Oregon, USA.
(19)Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium.
(20)Department of Clinical Genetics, Erasmus Medical Center, Rotterdam, the
Netherlands.
(21)Department of Pediatrics, Children’s Hospital Colorado and University of
Colorado Denver, Aurora, Colorado, USA.
(22)Department of Neurology, George Washington University Medical School,
Washington, DC, USA.
(23)1] INSERM U1079, Institute for Research and Innovation in Biomedicine (IRIB),
University of Rouen, Rouen, France. [2] Centre National de Référence pour les
Malades Alzheimer Jeunes (CNR-MAJ), Rouen University Hospital, Rouen, France. [3]
Department of Research, Rouvray Psychiatric Hospital, Sotteville-lès-Rouen,
France.
(24)1] INSERM U1079, Institute for Research and Innovation in Biomedicine (IRIB),
University of Rouen, Rouen, France. [2] Centre National de Référence pour les
Malades Alzheimer Jeunes (CNR-MAJ), Rouen University Hospital, Rouen, France. [3]
Department of Genetics, Rouen University Hospital, Rouen, France. [4] Department
of Neurology, Rouen University Hospital, Rouen, France.
(25)1] Department of Psychiatry, David Geffen School of Medicine, University of
California, Los Angeles, Los Angeles, California, USA. [2] Department of
Neurology, David Geffen School of Medicine, University of California, Los
Angeles, Los Angeles, California, USA.

Comment in
Mov Disord. 2015 Aug;30(9):1213.

Primary familial brain calcification (PFBC) is a neurological disease
characterized by calcium phosphate deposits in the basal ganglia and other brain
regions and has thus far been associated with SLC20A2, PDGFB or PDGFRB mutations.
We identified in multiple families with PFBC mutations in XPR1, a gene encoding a
retroviral receptor with phosphate export function. These mutations alter
phosphate export, implicating XPR1 and phosphate homeostasis in PFBC.

DOI: 10.1038/ng.3289
PMCID: PMC4516721
PMID: 25938945 [Indexed for MEDLINE]

Know more about